ArticleBrain, behavior, and immunity2025
Prenatal opioid exposure and maternal HCV infection impair microglia development and function: A patient-specific in vitro model.
Article in Brain, behavior, and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Opioids are a class of pain-relieving drugs known to cross the placental and blood brain barriers, exposing the fetus in utero. Rates of opioid use disorder amongst pregnant individuals in the United States are on the rise, and intravenous routes of opioid administration are highly associated with hepatitis C (HCV) infection. Newborns with prenatal opioid exposure (POE) are more likely to be small for gestational age and have increased rates of neurodevelopmental delay. Microglia are brain-resident macrophages that originate from yolk-sac precursors that play critical role in neurodevelopment. However, our understanding of the impact of POE on microglia maturation and function remains limited due to the scarcity of adequate models. Here, we leveraged a model of induced microglia-like cells (iMGL) derived from umbilical cord blood mononuclear cells to uncover the mechanisms underlying the impact of POE ± maternal HCV infection on microglia morphology, phenotype, function, and transcriptional profiles. Our study revealed that iMGL are closely related to primary microglia. iMGL derived from pregnancies with POE and maternal HCV infection exhibited an ameboid-like phenotype, characterized by smaller area/perimeter and diminished ramifications. This was accompanied by dysregulated expression of key microglia markers, impaired phagocytic capacity, but increased secretion of inflammatory mediators. Finally, transcriptional analysis of iMGL with and without stimulation by LPS revealed that POE ± maternal HCV infection desensitized iMGL to LPS stimulation. This immune tolerance of iMGL in utero was reflected by altered expression of genes important for neurological and fetal development, phagocytosis, and antimicrobial responses with POE ± maternal HCV infection. Overall, these findings highlight the utility of iMGLs as an accessible patient-specific model to study preconditioning and development of fetal microglia and provide insight into mechanisms underlying adverse neurodevelopmental outcomes in newborns with POE in presence and absence of maternal HCV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.